ALB and non-small cell lung carcinoma: Between January 2018 to December 2021, we retrospectively recruited 257 patients with advanced NSCLC, of whom 122(47.5%) advanced NSCLC patients were treated with camrelizumab plus albumin-bound paclitaxel regimen, and 135(52.5%) were camrelizumab monotherapy.